Heart:先心病患儿的很大摄氧量要明显低于正常对照儿童

2017-11-24 MedSci MedSci原创

本研究的目的旨在比较评估先天性心脏病患儿的心肺功能与性别、年龄匹配的正常儿童心肺功能的差异,并探究影响先心病患儿最大摄氧量(VO2max)的临床因素。本次横断面多中心临床研究纳入了496名先心患儿和302名正常对照,这些对象均接受了全面的心肺功能评估(CPET)。先心组患儿的平均VO2max与对照组平均VO2max值分别是预测值的93%±20% 和 107%±17%,VO2max在先心病组明显更低

本研究的目的旨在比较评估先天性心脏病患儿的心肺功能与性别、年龄匹配的正常儿童心肺功能的差异,并探究影响先心病患儿最大摄氧量(VO2max)的临床因素。本次横断面多中心临床研究纳入了496名先心患儿和302名正常对照,这些对象均接受了全面的心肺功能评估(CPET)。先心组患儿的平均VO2max与对照组平均VO2max值分别是预测值的93%±20% 和 107%±17%,VO2max在先心病组明显更低(37.8±0.3vs 42.6±0.4mL/kg/min, P<0.0001),每年VO2max值的下降值在先心病组中也更高(-0.84±0.10vs -0.19±0.14mL/kg/min/年, P<0.01),其中在男孩中为-0.72±0.14vs 0.11±0.19 mL/kg/min/年, P<0.01,女孩为-1.00±0.13 vs -0.55±0.21 mL/kg/min/年, P=0.05。经多元分析后,与VO2max相关的临床因素有:体重指数(BMI)、通气性无氧阈、女性、限制性通气障碍、右室收缩性高血压、三尖瓣关闭不全、心脏导管或手术次数、以及存在的遗传

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1775367, encodeId=dd301e753679f, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Wed Jun 13 16:46:00 CST 2018, time=2018-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311467, encodeId=817a131146eb9, content=<a href='/topic/show?id=a12628e0852' target=_blank style='color:#2F92EE;'>#先心病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28708, encryptionId=a12628e0852, topicName=先心病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25c8396, createdName=ssnine, createdTime=Sun Nov 26 07:46:00 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356581, encodeId=95fd135658162, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Nov 26 07:46:00 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562752, encodeId=1b9b1562e52b0, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sun Nov 26 07:46:00 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263985, encodeId=c4de26398567, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Nov 24 17:26:21 CST 2017, time=2017-11-24, status=1, ipAttribution=)]
    2018-06-13 amyloid
  2. [GetPortalCommentsPageByObjectIdResponse(id=1775367, encodeId=dd301e753679f, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Wed Jun 13 16:46:00 CST 2018, time=2018-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311467, encodeId=817a131146eb9, content=<a href='/topic/show?id=a12628e0852' target=_blank style='color:#2F92EE;'>#先心病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28708, encryptionId=a12628e0852, topicName=先心病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25c8396, createdName=ssnine, createdTime=Sun Nov 26 07:46:00 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356581, encodeId=95fd135658162, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Nov 26 07:46:00 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562752, encodeId=1b9b1562e52b0, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sun Nov 26 07:46:00 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263985, encodeId=c4de26398567, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Nov 24 17:26:21 CST 2017, time=2017-11-24, status=1, ipAttribution=)]
    2017-11-26 ssnine
  3. [GetPortalCommentsPageByObjectIdResponse(id=1775367, encodeId=dd301e753679f, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Wed Jun 13 16:46:00 CST 2018, time=2018-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311467, encodeId=817a131146eb9, content=<a href='/topic/show?id=a12628e0852' target=_blank style='color:#2F92EE;'>#先心病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28708, encryptionId=a12628e0852, topicName=先心病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25c8396, createdName=ssnine, createdTime=Sun Nov 26 07:46:00 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356581, encodeId=95fd135658162, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Nov 26 07:46:00 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562752, encodeId=1b9b1562e52b0, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sun Nov 26 07:46:00 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263985, encodeId=c4de26398567, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Nov 24 17:26:21 CST 2017, time=2017-11-24, status=1, ipAttribution=)]
    2017-11-26 zhaojie88
  4. [GetPortalCommentsPageByObjectIdResponse(id=1775367, encodeId=dd301e753679f, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Wed Jun 13 16:46:00 CST 2018, time=2018-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311467, encodeId=817a131146eb9, content=<a href='/topic/show?id=a12628e0852' target=_blank style='color:#2F92EE;'>#先心病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28708, encryptionId=a12628e0852, topicName=先心病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25c8396, createdName=ssnine, createdTime=Sun Nov 26 07:46:00 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356581, encodeId=95fd135658162, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Nov 26 07:46:00 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562752, encodeId=1b9b1562e52b0, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sun Nov 26 07:46:00 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263985, encodeId=c4de26398567, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Nov 24 17:26:21 CST 2017, time=2017-11-24, status=1, ipAttribution=)]
    2017-11-26 slcumt
  5. [GetPortalCommentsPageByObjectIdResponse(id=1775367, encodeId=dd301e753679f, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Wed Jun 13 16:46:00 CST 2018, time=2018-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311467, encodeId=817a131146eb9, content=<a href='/topic/show?id=a12628e0852' target=_blank style='color:#2F92EE;'>#先心病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28708, encryptionId=a12628e0852, topicName=先心病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25c8396, createdName=ssnine, createdTime=Sun Nov 26 07:46:00 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356581, encodeId=95fd135658162, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Nov 26 07:46:00 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562752, encodeId=1b9b1562e52b0, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sun Nov 26 07:46:00 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263985, encodeId=c4de26398567, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Nov 24 17:26:21 CST 2017, time=2017-11-24, status=1, ipAttribution=)]
    2017-11-24 1ddf0692m34(暂无匿称)

    学习了.涨知识

    0

相关资讯

宁光院士发布国人代谢指数 可评估心血管发病概率

11月23日,中华医学会糖尿病学分会第二十一次全国学术会议(CDS2017)在重庆盛大召开。

JACC:磺达肝癸钠治疗肝素引起的血小板减少症安全有效

肝素引起的血小板减少症(HIT)可能会造成致命的危险,HIT常常通过非肝素抗凝药比如阿加曲班、重组水蛭素或者达那肝素来治疗。本研究的目的旨在比较评估不同抗凝剂治疗HIT的安全性和有效性。本次多中心临床研究纳入了195例诊断为HIT的住院病人,并且有至少一个中等临床HIT风险,接受≥1个剂量上述抗凝药。主要终点事件为HIT特异并发症的发生(静脉/动脉血栓栓塞事件、截肢、复发性/持续性血小板减少、皮肤

JACC:NOACs相比华法林对房颤患者肾脏影响更小

终身口服抗凝药,比如华法林和非维生素K拮抗剂口服抗凝药(NOAC),被推荐用来预防房颤患者卒中的发生,最新的研究认为在肾功能影响方面NOACs可能比华法林更佳。本研究的目的旨在比较评估四种口服抗凝药(阿哌沙班、达比加群、利伐沙班和华法林)对四种肾脏预后结局的影响:肾小球滤过率(eGFR)下降≥30%、血清肌酐水平加倍、急性肾损伤(AKI)和肾衰。本研究纳入了2010年十月至2016年四月开始口服抗

Kidney int:LDL、炎症以及心血管风险之间是一种怎样的关系?

一些炎症标志物,包括血浆C-反应蛋白(CRP),与心血管疾病的风险增加有关,并且有研究者认为这种关联存在着因果关系。然而,炎症与心血管疾病之间的关系尚未在慢性肾病患者中进行深入研究。近期,一项发表在杂志Kidney int上的研究旨在评估这两者之间的关系。研究者们使用心脏和肾脏保护研究(SHARP)的数据评估了循环系统汇总CRP和LDL胆固醇水平之间的关系以及血管和非血管结果的风险。主要血管事件被

Nat Commun:科学家发现再生血管的关键,为心血管病治疗带来新曙光

由Sanford Burnham Prebys医学发现研究所(SBP)的研究人员领导的一项新研究确定了一个信号通路,该通路对血管生成以及来自已有血管的新血管的生长是必不可少的。 “自然通讯”杂志发表的研究结果可能改善目前的策略,改善缺血组织的血流量,如动脉粥样硬化和糖尿病相关的外周血管疾病。

JAHA:胸段硬膜外麻醉可作为难治性室速的治疗选择

目前,一些调节自主神经系统的新疗法,比如胸段硬膜外麻醉(TEA),在一些小型的系列研究中被证实对难治性室速(VT)有较好的疗效。然而,这是否可以真正作为治疗难治性室速的一个方法尚未阐明。本研究回顾分析了2005年至2016年11例接受胸段硬膜外麻醉的难治性室速患者,对其临床特征、预后结局和治疗管理进行了全面分析。在临床表现上,有7例(64%)患者为持续性室速,3例(27%)患者为多相室速,8例(7